3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
2
CNS
2
Thoracic
1
Other hematologic neoplasm
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Pancreatic Neoplasms
2
Ovarian Neoplasms
2
Neoplasm Metastasis
2
Lung Neoplasms
2
Breast Neoplasms
2
Urinary Bladder Neoplasms
1
Thyroid Neoplasms
1
Stomach Neoplasms
1
Sarcoma
1
Prostatic Neoplasms
1
Neoplasms
1
Melanoma
1
Liver Neoplasms
1
Leukemia
1
Kidney Neoplasms
1
Glioblastoma
1
Esophageal Neoplasms
1
Disease
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Bronchogenic
1
Interventions
pembrolizumab
10
Gemcitabine
8
Cyclophosphamide
7
Filgrastim
5
Docetaxel
5
Carboplatin
5
Trastuzumab
4
Surveys and Questionnaires
4
Nivolumab
4
Doxorubicin
4
Cisplatin
4
poly ICLC
3
pazopanib
3
atezolizumab
3
aldesleukin
3
Taxes
3
Radiotherapy
3
Paclitaxel
3
Oncolytic Virotherapy
3
Irinotecan
3
Ipilimumab
3
Injections
3
Drug Therapy
3
Cetuximab
3
Capecitabine
3
Albumin-Bound Paclitaxel
3
130-nm albumin-bound paclitaxel
3
spartalizumab
2
palbociclib
2
liposomal doxorubicin
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Sarcoma
×
Interleukin-15
×
Breast
×
Clear all
NCT07410676
2026-02-18
EBNK-ST-001
Essen Biotech
Phase 1/2
Recruiting
83 enrolled